Becker's ASC

Blood test may help identify GI cancer risk: Study

A recent study has identified a potential new tool to help detect gastrointestinal cancers — the platelet-to-high-density lipoprotein ratio, or PHR. Researchers analyzed data from more than 19,000 ...
ascopubs.org

EQUITY GI: A prospective study to enhance quality, inclusivity, and trial participation in Black patients with gastrointestinal cancer.

Comparing outcomes for early and late drainage of malignant ascites. Background: Black individuals, including African Americans, experience a disproportionate cancer burden and exhibit the lowest ...
News Medical

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Among the most recently approved drugs for weight management, glucagon-like peptide 1 (GLP-1) agonists have garnered considerable attention; however, the effects of these drugs on the gastrointestinal ...
Business Wire

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
ascopubs.org

Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine

Capecitabine is an oral chemotherapy used to treat many gastrointestinal cancers. Its complex dosing and narrow therapeutic index make medication adherence and toxicity management crucial for quality ...